Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00199342 · ClinicalTrials.gov registry record · Phase 1
A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma
A Phase 1 study, sponsored by Kyowa Kirin.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00199342: Clinical Trial Phase 1 study, sponsored by Kyowa Kirin.
NCT00199342 is a Phase 1 study that was terminated before completion, run by Kyowa Kirin. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00199342, a Phase 1 study, was terminated before completion, sponsored by Kyowa Kirin.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a dose escalating cohort study to determine the maximum tolerated dose (MTD) of KW-2871 (in dose cohorts of 60, 80, and 100 mg/m2) when administered with a specified premedication regimen (ranitidine, diphenhydramine, and dexamethasone). KW-2871 will be administered at 14-day intervals.
Primary Outcome
Until determination of MTD or recommended dose for evaluation
Interventions
- DRUG KW-2871
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2004-11 |
| Phase | Phase 1 |
Why NCT00199342 stopped before completion
NCT00199342 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which KW-2871 is the first listed.
NCT00199342 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00199342 about?
NCT00199342 is a clinical study titled "A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma". This is a dose escalating cohort study to determine the maximum tolerated dose (MTD) of KW-2871 (in dose cohorts of 60, 80, and 100 mg/m2) when administered with a specified premedication regimen (ranitidine, diphenhydramine, and dexamethasone). KW-2871 will be administered at 14-day intervals.
What is the current status of trial NCT00199342?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2004-11.
What interventions are being tested in trial NCT00199342?
The interventions under investigation include: KW-2871 (DRUG).
Who is sponsoring clinical trial NCT00199342?
This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00199342's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia